KLRK1 and neoplasm: Therefore, activating the NKG2D-NKG2DL signalling pathway by increasing NKG2D expression on immune cells and NKG2DL expression on AML cells can not only improve the tumour-killing ability of CAR T cells but also prevent AML relapse.